Divis Laboratories Limited reduced its greenhouse gas emissions by approximately 13,500 TCO2e during the financial year 2025-26, according to its Business Responsibility and Sustainability Report. The Hyderabad-based pharmaceutical manufacturer achieved this reduction through initiatives such as using biomass briquettes for boiler operations and implementing green chemistry principles. The company also conserved 1,59,500 kiloliters of water and 8,290 gigajoules of energy during the same period.

Sustainability Targets and Performance

The company has committed to reaching net-zero greenhouse gas emissions across the value chain by FY 2050, with targets validated by the Science Based Targets initiative (SBTi). For the near term, Divi’s aims to reduce absolute scope 1 and 2 GHG emissions by 58.8% by FY 2034 from a FY 2024 base year. It also targets a 35% reduction in absolute scope 3 GHG emissions within the same timeframe.

Operational Metrics and Compliance

Divi’s Laboratories operates four plants and one office nationally, with two international offices. The company reported exports contributing 89% to its total turnover. Bureau Veritas (India) Private Limited provided reasonable assurance for the BRSR core indicators. The report confirms compliance with applicable environmental laws and regulations in India.

Employee Safety and Well-being

The company recorded no fatalities, major fires, explosions, or toxic gas leaks during FY 2025-26. The lost time injury severity rate stood at 0.14, well below the target of 0.3. The workforce comprised 12,119 employees and 7,173 workers, with women constituting 14.37% of the total employee strength and 0.07% of the total worker strength.

Waste and Water Management

Divi’s implemented a Zero Liquid Discharge (ZLD) system at its Unit-I in Telangana, covering all industrial effluents and domestic wastewater. The company reduced approximately 46 metric tonnes of plastic packaging waste during the year. Approximately 86% of hazardous waste generated was sent for co-processing and recyclers.

Divi's Laboratories Limited disclosed on April 06, 2026, that its promoter group has not encumbered any shares during the financial year ended March 31, 2026. The declaration, submitted to the National Stock Exchange of India and BSE Limited, confirms that no shares were pledged directly or indirectly by the promoters or Persons Acting in Concert (PAC). This disclosure is significant for shareholders as it indicates the absence of leverage risk against the promoter holding, which accounts for over half of the company's total equity.

The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Dr. Murali K. Divi, Promoter and Managing Director, signed the disclosure on behalf of the promoter group. The statement covers the promoter group's entire shareholding, ensuring transparency regarding the ownership status of the key stakeholders in the company.

The promoter group, including Dr. Murali K. Divi and other PAC members, collectively holds 13,75,67,000 equity shares. This represents 51.82% of the company's total share capital and total diluted share capital. The largest individual holdings within the group are attributed to Dr. Kiran Satchandra Divi and Nilima Prasad Divi, each holding 20.34% of the total share capital.

The following table details the shareholding pattern of the promoter group as disclosed in the filing:

The confirmation of no encumbrance provides stability to the shareholding structure of Divis Laboratories . The document was signed in Hyderabad on April 06, 2026, and a copy was forwarded to the Audit Committee of the company for its records.